KR910002897A - 에리트로포이에틴(epo)펩타이드 및 이에 대한 항체 - Google Patents

에리트로포이에틴(epo)펩타이드 및 이에 대한 항체 Download PDF

Info

Publication number
KR910002897A
KR910002897A KR1019900011291A KR900011291A KR910002897A KR 910002897 A KR910002897 A KR 910002897A KR 1019900011291 A KR1019900011291 A KR 1019900011291A KR 900011291 A KR900011291 A KR 900011291A KR 910002897 A KR910002897 A KR 910002897A
Authority
KR
South Korea
Prior art keywords
epo
epitope
antibody
peptide
antibodies
Prior art date
Application number
KR1019900011291A
Other languages
English (en)
Other versions
KR0175657B1 (ko
Inventor
피비 마티아스
스튀베르 베르너
Original Assignee
스타인, 부그
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스타인, 부그, 베링베르케 아크티엔게젤샤프트 filed Critical 스타인, 부그
Publication of KR910002897A publication Critical patent/KR910002897A/ko
Application granted granted Critical
Publication of KR0175657B1 publication Critical patent/KR0175657B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음.

Description

에리트로포이에틴(EPO)펩타이드 및 이에 대한 항체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 직접적인 에리트로포이에탄-결합분석도이다.
제2도는 rhuEPO-특이적 항 혈청에 의한 재조합 사람 에리트로포이틴 (rhuEPO) 의 생물학적 활성억제도이다.
제3도는 항-EPO-P2-KLH혈청에 의한 억제의 역위도이다.

Claims (17)

  1. 천연 EPO의 아미노산 위치를 기준으로, 아미노산 1 내지 35(P4)번, 7내지 23(p4/1)번, 44내지 78(P3)번, 52내지 63(P3/1)번, 74내지 109(P1)번, 84내지 95(P1/1)번, 93내지 137(P5)번, 110내지 123(P5/1)번, 142내지 166(P2)번 또는 152내지 166(P2/1)번을 필수적으로 포함하는 에리트로포이에틴(EPO)펩타이드.
  2. 제1항에 있어서, 합성된 EPO펩타이드.
  3. 제1항 또는 2항에 있어서, 하기 아미노산 서열 중 하나를 지니는 EPO펩타이드;
    P1 VLRGQALLVNSSQPWEPLQHVDKAVSGLRSLTTLL; P1/1SSQPWEPLQLHV;
    P3 NEMITVPDTKVNFYAWKRMETGQQAVEVWGGLALLSEA;
    P3/1 KRMEVGGAVEV;
    P4 APPRLOCDSRVLERTLLEAKEAENITTGCAEHCSL;
    P4/1 CDSEVLERYLLEAKEAE;
    P5 LHVDKAVSGLRSLTTLLRALRAQKEAISPPDAASAAPLRTITADT; 또는
    P5/1 RALRAQKEAISPPD.
  4. 제1항 또는 2항에 있어서, 하기 아미노산 서열중 하나를 지니는 EPO펩타이드:
    P2 FRKLFRVYSNFLRGKLKYTGEACRTGDR, 또는 P2/1 KLKLYTGEACRTGDR.
  5. 에피토프-특이적 항-EPO 항체 (에피토프 하나 이상의 펩타이드로 이루어지거나 펩타이드 서열의 하나이상의 단편으로 이루어진다)의 제조를 위한 제1항 내지 4항중 어느 한 항에 따른 EPO펩타이드의 용도.
  6. 제5항에 있어서, 에프토프-특이적 항-EPO항체가 모노클로날 항체인 용도.
  7. 제1항 내지 4항중 어느 한 항에 다른 EPO펩타이드 및/또는 제5항에 따른 EPO에피토프에 대한 에피토프-특이적 항-EPO 항체.
  8. 제6항에 있어서, 모노클로날 항체인 에피토프-특이적 항- EPO 항체.
  9. 제7항 또는 8항에 있어서, EPO의 생물학적 활성을 중화시키는 에피토프-특이적 항-EPO 항체.
  10. EPO-중화 항체의 결합 영역에 대한 제9항에 따른 항-전유전물질형 항체.
  11. EPO, EPO유도체 또는 EPO펩타이드를 정제하기 위한. 제7항 내지 제9항중 어느 한 항에 따른 에피토프-특이적 항-EPO항체의 용도.
  12. EPO검출, 바람직하게 에피토프-특이적 검출을 위한 제7항 내지 9항중 어느 한 항에 따른 에피토프-특이적 항-EPO항체를 함유하는 전단보조제.
  13. 항-EPO항체 검정을 위한 제1항 내지 제4항중 어느 한 항에 따른 EPO펩타이드를 함유하는 진단보조제.
  14. 제1항 내지 제4항중 어느 한 항에 따른 EPO펩타이드를 적어도 하나 또는 제9항에 따른 에피토프-특이적 항-, EPO항체 및, 필요한 경우, 약학적으로 허용되는 보조제 및 부가제를 함유하는 약제.
  15. 제10항에 따른 항-전유전물질 항체 및, 필요한 경우, 약학적으로 허용되는 보조제 및 부가제를 함유하는 약제.
  16. 제14항에 또는 15항에 있어서, 조혈 조절 장애의 치료를 위한 약제.
  17. 중화항체 또는 EPO 수용체의 검출을 위한 제10항에 따른 항-전유전물질형 항체를 함유하는 진단보조제,
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900011291A 1989-07-26 1990-07-25 에리트로포이에틴 펩타이드 및 이에 대한 항체 KR0175657B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP3924746.5 1989-07-26
DE3924746A DE3924746A1 (de) 1989-07-26 1989-07-26 Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
DEP39247465 1989-07-26

Publications (2)

Publication Number Publication Date
KR910002897A true KR910002897A (ko) 1991-02-26
KR0175657B1 KR0175657B1 (ko) 1999-04-01

Family

ID=6385895

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900011291A KR0175657B1 (ko) 1989-07-26 1990-07-25 에리트로포이에틴 펩타이드 및 이에 대한 항체

Country Status (13)

Country Link
US (2) US5106954A (ko)
EP (1) EP0410246B1 (ko)
JP (1) JP3155002B2 (ko)
KR (1) KR0175657B1 (ko)
AT (1) ATE161577T1 (ko)
AU (1) AU648506B2 (ko)
CA (1) CA2021912C (ko)
DE (2) DE3924746A1 (ko)
DK (1) DK0410246T3 (ko)
ES (1) ES2111524T3 (ko)
GR (1) GR3026096T3 (ko)
IE (1) IE902707A1 (ko)
PT (1) PT94813B (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100400637B1 (ko) * 1996-02-06 2004-03-10 씨제이 주식회사 생물학적으로유용한펩타이드
KR20150090101A (ko) * 2012-12-05 2015-08-05 노파르티스 아게 Epo를 표적화하는 항체에 대한 조성물 및 방법

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6932968B1 (en) * 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB2270695B (en) * 1992-09-18 1996-06-05 Oxford Res Support Co Ltd Antibodies that activate plasminogen in the manner of streptokinase
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
ES2210374T3 (es) * 1995-06-07 2004-07-01 Ortho Pharmaceutical Corporation Compuestos y peptidos que se unen al receptor de eritropoyetina.
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
ES2523599T3 (es) * 1997-12-03 2014-11-27 Roche Diagnostics Gmbh Eritropoyetina de gran actividad específica
MXPA01011264A (es) * 1999-05-07 2002-07-02 Genentech Inc Nuevos polipeptidos de eritropoyetina de chimpance (chepo) y aciodos nucleicos que codifican los mismos.
KR100524041B1 (ko) * 1999-05-07 2005-10-27 제넨테크, 인크. 신규 침팬지 에리쓰로포이에틴 (chepo) 폴리펩티드 및 이를 코딩하는 핵산
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
WO2001077677A1 (en) * 2000-04-05 2001-10-18 Lee Jong Y Detection of erythropoietin and erythtropoietin receptor
JP2003530839A (ja) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション アルブミン融合タンパク質
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CA2437272A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified erythropoietin (epo) with reduced immunogenicity
US7300916B2 (en) * 2001-02-27 2007-11-27 Yoshiko Yasuda Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
WO2003010173A1 (en) * 2001-07-26 2003-02-06 Tagra Biotechnologies Ltd. Stabilized derivatives of ascorbic acid -3-phosphate
US6930086B2 (en) * 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277910A1 (en) * 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1527094B1 (en) * 2002-08-09 2008-07-16 MERCK PATENT GmbH T-cell epitopes in erythropoietin
EP1608672A4 (en) * 2003-04-02 2007-11-21 Epimmune Inc PEPTIDES, POLYPEPTIDES AND PROTEINS OF REDUCED IMMUNOGENICITY AND METHODS OF PRODUCTION THEREOF
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US20040266993A1 (en) * 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
WO2006050959A2 (en) * 2004-11-10 2006-05-18 Aplagen Gmbh Molecules which promote hematopoiesis
US7589063B2 (en) * 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
US20090118195A1 (en) * 2004-11-10 2009-05-07 Hans-Georg Frank Molecules Which Promote Hematopoiesis
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
JP2008546732A (ja) * 2005-06-23 2008-12-25 アプラゲン ゲーエムベーハー 多価化合物
SG2014007868A (en) 2005-08-05 2014-05-29 Araim Pharmaceuticals Inc Tissue protective peptides and uses thereof
SG170086A1 (en) * 2006-03-09 2011-04-29 Aplagen Gmbh De Modified molecules which promote hematopoiesis
EP2134862A4 (en) * 2007-03-12 2011-04-20 Univ Utah Res Found COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETIC MICROVASCULAR COMPLICATIONS
KR20190085187A (ko) 2008-01-22 2019-07-17 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
MX346001B (es) 2008-09-26 2017-03-01 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
JP2018525389A (ja) 2015-08-12 2018-09-06 ノバルティス アーゲー 眼障害を治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4558005A (en) * 1982-09-13 1985-12-10 University Patents, Inc. Monoclonal anti-erythropoietin
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100400637B1 (ko) * 1996-02-06 2004-03-10 씨제이 주식회사 생물학적으로유용한펩타이드
KR20150090101A (ko) * 2012-12-05 2015-08-05 노파르티스 아게 Epo를 표적화하는 항체에 대한 조성물 및 방법
KR20210035921A (ko) * 2012-12-05 2021-04-01 노파르티스 아게 Epo를 표적화하는 항체에 대한 조성물 및 방법

Also Published As

Publication number Publication date
KR0175657B1 (ko) 1999-04-01
PT94813B (pt) 1997-04-30
US5712370A (en) 1998-01-27
ATE161577T1 (de) 1998-01-15
DE59010787D1 (de) 1998-02-05
CA2021912C (en) 2001-11-27
JP3155002B2 (ja) 2001-04-09
EP0410246B1 (de) 1997-12-29
CA2021912A1 (en) 1991-01-27
EP0410246A1 (de) 1991-01-30
GR3026096T3 (en) 1998-05-29
DE3924746A1 (de) 1991-01-31
IE902707A1 (en) 1991-02-27
JPH0381294A (ja) 1991-04-05
US5106954A (en) 1992-04-21
AU5977890A (en) 1991-01-31
DK0410246T3 (da) 1998-08-31
PT94813A (pt) 1991-03-20
AU648506B2 (en) 1994-04-28
ES2111524T3 (es) 1998-03-16

Similar Documents

Publication Publication Date Title
KR910002897A (ko) 에리트로포이에틴(epo)펩타이드 및 이에 대한 항체
Surh et al. Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope (s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex
Colombatti et al. Biosynthesis of chick type VI collagen. I. Intracellular assembly and molecular structure.
BR8606615A (pt) Polipeptideos complementares a peptideos ou proteinas tendo uma sequencia de aminoacidos ou sequencia de codificacao de nucleotidios conhecida ao menos parcialmente e metodos de projeto dos mesmos
DK0536275T3 (da) Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
BR9506059A (pt) Proteinas envelopes purificadas de virus c para uso de diagnóstico e terapêutico
WO1996029605A3 (en) Compounds and methods for the dectection of t. cruzi infection
DE68925226T2 (de) Monoklonale Antikörper
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
Böhmer et al. Specific neutralizing antiserum against a polypeptide growth inhibitor for mammary cells purified from bovine mammary gland
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
CA1256795A (en) Anti-idiotype antibodies induced by synthetic polypeptides
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
WO1994004675A3 (en) Dna sequence encoding a novel member of the steroid and thyroid hormone receptor family
Senecal et al. Autoantibodies to major and minor nuclear lamins are not restricted to autoimmune diseases
KR940005665A (ko) 분리된 폴리펩티드, 이를 암호하는 핵산 분자, 상기 폴리펩티드를 포함하는 조성물 및 이를 사용하는 방법
FR2571146B1 (fr) Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
Gunson et al. Rat parietal yolk sac basement membrane. An investigation of the antigenic determinants using a radioimmunoassay.
Portmann et al. Further Characterization of the Thyroid Microsomal Antigen by Monoclonal Antibodies
Marchalonis et al. Introduction—The Immunoglobulin-Like T Cell Receptor Problem

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20111020

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee